Literature DB >> 26806100

Evaluation of [11C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT.

Min-Liang Pan1, Meenakshi T Mukherjee1, Himika H Patel1, Bhavin Patel1, Cristian C Constantinescu1, M Reza Mirbolooki1, Christopher Liang1, Jogeshwar Mukherjee1.   

Abstract

OBJECTIVE: Alzheimer's disease (AD) is a neurodegenerative disease characterized by Aβ plaques in the brain. The aim of this study was to evaluate the effectiveness of a novel radiotracer, 4-[(11) C]methylamino-4'-N,N-dimethylaminoazobenzene ([(11)C]TAZA), for binding to Aβ plaques in postmortem human brain (AD and normal control (NC)).
METHODS: Radiosyntheses of [(11)C]TAZA, related [(11)C]Dalene ((11)C-methylamino-4'-dimethylaminostyrylbenzene), and reference [(11)C]PIB were carried out using [(11)C]methyltriflate prepared from [(11) C]CO(2) and purified using HPLC. In vitro binding affinities were carried out in human AD brain homogenate with Aβ plaques labeled with [(3) H]PIB. In vitro autoradiography studies with the three radiotracers were performed on hippocampus of AD and NC brains. PET/CT studies were carried out in normal rats to study brain and whole body distribution.
RESULTS: The three radiotracers were produced in high radiochemical yields (>40%) and had specific activities >37 GBq/μmol. TAZA had an affinity, K(i) = 0.84 nM and was five times more potent than PIB. [(11)C]TAZA bound specifically to Aβ plaques present in AD brains with gray matter to white matter ratios >20. [(11)C]TAZA was displaced by PIB (>90%), suggesting similar binding site for [(11)C]TAZA and [(11)C]PIB. [(11)C]TAZA exhibited slow kinetics of uptake in the rat brain and whole body images showed uptake in interscapular brown adipose tissue (IBAT). Binding in brain and IBAT were affected by preinjection of atomoxetine, a norepinephrine transporter blocker.
CONCLUSION: [(11)C]TAZA exhibited high binding to Aβ plaques in human AD hippocampus. Rat brain kinetics was slow and peripheral binding to IBAT needs to be further evaluated.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Alzheimer's disease; PET imaging; [11C]TAZA; brown adipose tissue; human Aβ plaque; norepinephrine transporter

Mesh:

Substances:

Year:  2016        PMID: 26806100      PMCID: PMC5358321          DOI: 10.1002/syn.21893

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  48 in total

1.  Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates.

Authors:  Karin A Stephenson; Rajesh Chandra; Zhi-Ping Zhuang; Catherine Hou; Shunichi Oya; Mei-Ping Kung; Hank F Kung
Journal:  Bioconjug Chem       Date:  2007 Jan-Feb       Impact factor: 4.774

2.  Amyloid imaging in vivo: implications for Alzheimer's disease management.

Authors:  Nicolaas Plg Verhoeff
Journal:  Expert Opin Med Diagn       Date:  2007-11

3.  Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents.

Authors:  D Hadrich; F Berthold; E Steckhan; H Bönisch
Journal:  J Med Chem       Date:  1999-08-12       Impact factor: 7.446

4.  Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future.

Authors:  Manuela Ariza; Hartmuth C Kolb; Dieder Moechars; Frederik Rombouts; José Ignacio Andrés
Journal:  J Med Chem       Date:  2015-02-25       Impact factor: 7.446

5.  A template for spatial normalisation of MR images of the rat brain.

Authors:  Petra Schweinhardt; Peter Fransson; Lars Olson; Christian Spenger; Jesper L R Andersson
Journal:  J Neurosci Methods       Date:  2003-10-30       Impact factor: 2.390

6.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

7.  In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

Authors:  Michelle T Fodero-Tavoletti; David P Smith; Catriona A McLean; Paul A Adlard; Kevin J Barnham; Lisa E Foster; Laura Leone; Keyla Perez; Mikhalina Cortés; Janetta G Culvenor; Qiao-Xin Li; Katrina M Laughton; Christopher C Rowe; Colin L Masters; Roberto Cappai; Victor L Villemagne
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

8.  11C-Fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain.

Authors:  Jogeshwar Mukherjee; Bingzhi Shi; Bradley T Christian; Sankha Chattopadhyay; Tanjore K Narayanan
Journal:  Bioorg Med Chem       Date:  2004-01-02       Impact factor: 3.641

9.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

10.  11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease.

Authors:  Masahiro Ono; Alan Wilson; Jose Nobrega; David Westaway; Paul Verhoeff; Zhi-Ping Zhuang; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2003-08       Impact factor: 2.408

View more
  7 in total

1.  NRM 2021 Abstract Booklet.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2021-12       Impact factor: 6.960

2.  Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors-potential approaches to facilitate Aβ plaque removal in Alzheimer's disease brain.

Authors:  Gurleen K Samra; Kenneth Dang; Heather Ho; Aparna Baranwal; Jogeshwar Mukherjee
Journal:  Med Chem Res       Date:  2018-04-07       Impact factor: 1.965

3.  Development and evaluation of [125 I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain.

Authors:  Jogeshwar Mukherjee; Christopher Liang; Krystal K Patel; Phuc Q Lam; Rommani Mondal
Journal:  Synapse       Date:  2020-08-06       Impact factor: 2.562

4.  Development and evaluation of [18F]Flotaza for Aβ plaque imaging in postmortem human Alzheimer's disease brain.

Authors:  Harsimran Kaur; Megan R Felix; Christopher Liang; Jogeshwar Mukherjee
Journal:  Bioorg Med Chem Lett       Date:  2021-06-01       Impact factor: 2.940

Review 5.  PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias.

Authors:  Xin Y Zhang; Zhen L Yang; Guang M Lu; Gui F Yang; Long J Zhang
Journal:  Front Mol Neurosci       Date:  2017-11-01       Impact factor: 5.639

6.  [124I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer's Disease.

Authors:  Grace A H Nguyen; Christopher Liang; Jogeshwar Mukherjee
Journal:  Molecules       Date:  2022-07-17       Impact factor: 4.927

Review 7.  Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and Obesity.

Authors:  Jogeshwar Mukherjee; Aparna Baranwal; Kimberly N Schade
Journal:  Curr Diabetes Rev       Date:  2016
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.